GLP-1 receptor agonists improve cholesterol, but they do not all move the lipid panel the same way. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) mostly improve lipids by reducing body weight, insulin resistance, and liver fat. Triglycerides move more than LDL.
Retatrutide goes further because it adds a liver-facing glucagon signal. In the MASLD-selected substudy, that produced up to 86% liver-fat reduction²; in the obesity trial, triglycerides fell roughly 35-45% at higher doses⁴. Its LDL effect appears to come through lower liver secretion of ANGPTL3/8¹⁰, which removes a brake on lipid clearance. That is the important correction: this is not a PCSK9-degradation story.
Your liver packages fat into cholesterol-carrying particles. When less fat reaches the liver, or when the liver is pushed to burn more of it, fewer triglyceride-rich particles stay in circulation.
At a Glance: GLP-1 Effects on Lipid Panels
| Parameter | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Triglycerides | -15% to -25% | -20% to -30% | -35% to -45% |
| LDL Cholesterol | -3% to -5% | -5% to -8% | -12% to -20% |
| HDL Cholesterol | +2% to +5% | +7% to +8% | Flat / mixed |
| Liver Fat | Meaningful reduction | Up to ~50% placebo-adjusted in non-T2D obesity | ~86% in MASLD-selected substudy |
| MASH Resolution | 62.9% (ESSENCE)⁷ | 62% (SYNERGY-NASH)⁸ | TBD |
| Mechanism | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
Note: MASH resolution and liver-fat reduction are different endpoints. Liver fat measures lipid stored in the liver on imaging. MASH resolution measures inflammatory liver disease clearing on biopsy. ESSENCE recorded 62.9% MASH resolution on semaglutide 2.4 mg vs 34.1% placebo; SYNERGY-NASH recorded 62% on tirzepatide 15 mg vs 10% placebo. Retatrutide has the strongest MRI liver-fat signal, but its MASH biopsy endpoint is not published yet. Lipid responses can also be smaller in type 2 diabetes because baseline metabolic dysfunction changes the response curve.
How GLP-1 Drugs Lower Cholesterol
All three drugs reduce food intake, and weight loss alone improves lipids. A 10% body-weight drop often moves triglycerides more than LDL. But weight loss alone does not explain why retatrutide produces such large liver-fat and triglyceride changes.
Semaglutide: GLP-1 Only (Ozempic, Wegovy)
Semaglutide activates only GLP-1 receptors. The lipid benefits come primarily from:
- Weight loss reducing the fatty acid load the liver has to process
- Some liver-output effects — less substrate and improved metabolic signaling reduce VLDL production (the particles that carry triglycerides)
This produces meaningful triglyceride reduction (15-25%) and modest LDL improvement (3-5%). The SELECT trial showed Ozempic/Wegovy reduced cardiovascular events by 20%.¹ Lipid improvements were part of the overall metabolic benefit.
Tirzepatide: GLP-1 + GIP (Mounjaro, Zepbound)
Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) receptor activation. GIP receptors sit on fat cells and in the liver, providing additional metabolic signaling:
- Enhanced adipocyte metabolism — fat cells respond better to signals telling them to release or burn fat
- Improved nutrient partitioning — dietary fat gets directed toward oxidation rather than storage
- Greater weight loss — tirzepatide produces about 50% more weight loss than semaglutide at comparable doses
This translates to stronger lipid effects: about 20-30% triglyceride reduction in major obesity trials, and a large liver-fat signal in MRI studies. The cleanest non-diabetic obesity anchor is SURMOUNT-J, where the 15 mg dose produced about a 50% placebo-adjusted liver-fat reduction. Tirzepatide is stronger than semaglutide here, but still works mostly through weight loss, insulin improvement, and fat-tissue signaling.
Retatrutide: GLP-1 + GIP + Glucagon
Retatrutide adds the piece that fundamentally changes the equation: glucagon receptor activation.
Glucagon is insulin's counter-signal. Where insulin pushes storage, glucagon pushes fuel release and oxidation. Glucagon receptors are concentrated in the liver, so retatrutide shifts the liver toward burning stored fat instead of packaging it into triglyceride-rich particles.
This is not a passive effect of eating less. It's an active signal telling the liver to mobilize fat.
The results in Phase 2 and MASLD substudy data:
- 86% liver fat reduction in the MASLD-selected substudy — with 93% of patients on the highest dose achieving complete clearance on MRI (below 5% liver fat content by imaging — a different endpoint from the histologic MASH resolution measured in ESSENCE and SYNERGY-NASH)
- 35-45% triglyceride reduction — roughly double what semaglutide achieves
- Meaningful LDL reduction (~20% at the highest dose) — larger than semaglutide or tirzepatide, but still not statin-like. The mechanism is distinct: glucagon receptor activation directly reduces hepatic ANGPTL3/8¹⁰ secretion, removing a brake on lipoprotein lipase and helping clear triglyceride-rich particles and LDL from blood.
For lipid improvement specifically, the glucagon component is the differentiator. Semaglutide and tirzepatide improve lipids as a downstream effect of weight loss and metabolic improvement. Retatrutide directly targets the liver's fat-handling machinery.
Clinical Trial Evidence
Semaglutide Trials
| Trial | Population | Triglycerides | LDL | Other |
|---|---|---|---|---|
| SELECT | Obesity + CV disease (N=17,604) | -17% | -4% | 20% MACE reduction (major adverse cardiovascular events: heart attack, stroke, CV death) |
| STEP-1⁵ | Obesity (N=1,961) | -18% | -5% | — |
| STEP-2 | Obesity + T2D (N=1,210) | -22% | -3% | — |
Consistent pattern: substantial triglyceride reduction, modest LDL improvement.
Tirzepatide Trials
| Trial | Population | Triglycerides | LDL | Liver Fat |
|---|---|---|---|---|
| SURMOUNT-1⁶ | Obesity (N=2,539) | -22% to -30% | -5% to -8% | — |
| SURMOUNT-J MRI | Non-T2D obesity | Strong reduction | Modest | ~50% placebo-adjusted liver-fat reduction |
| SURPASS-3 MRI | T2D (MRI substudy) | -25% | — | ~47% |
| SURMOUNT-5⁹ | Obesity (vs semaglutide) | — | — | 47% more weight loss than sema |
Retatrutide Trials
| Trial | Population | Triglycerides | LDL | Liver Fat |
|---|---|---|---|---|
| Phase 2 (NEJM) | Non-diabetic obesity | ~-40% | ~-20% (12mg) | — |
| Phase 2 (T2D) | Type 2 diabetes | — | — | — |
| MASLD Substudy | Obesity + fatty liver | — | — | -86% (93% achieved resolution) |
The ~20% LDL reduction at the 12 mg dose is notable⁴. The newer mechanism work points to glucagon-driven ANGPTL3/8¹⁰ suppression in hepatocytes, not PCSK9 degradation. That matters because it explains why retatrutide looks different from a statin: it improves the liver's fat-export and lipid-clearance environment rather than blocking cholesterol synthesis.
Population note: The lipid data above comes primarily from the non-diabetic obesity trial. In type 2 diabetes, where GIP signaling is impaired and metabolic baselines differ, lipid responses may vary. Separate T2D trials reported similar directional improvements but with different magnitudes.
Phase 3 trials will provide larger-scale confirmation, but the magnitude of effect on liver fat, triglycerides, and LDL is qualitatively different from semaglutide and tirzepatide.
What This Means for Different Lipid Profiles
For cardiovascular event reduction specifically, semaglutide has the evidence. For metabolic dysfunction where liver fat is driving risk, retatrutide's mechanism may prove more relevant — but that awaits outcome trials.
| Concern | Semaglutide | Tirzepatide | Retatrutide | Notes |
|---|---|---|---|---|
| High Triglycerides | -15% to -25% | -20% to -30% | -35% to -45% | Retatrutide's glucagon effect is most direct for severe cases (>500 mg/dL) |
| Fatty Liver (MASLD) | Meaningful reduction | Up to ~50% placebo-adjusted | ~86% in MASLD-selected substudy | Reta has the strongest imaging signal; MASH biopsy data is still pending |
| LDL Cholesterol | -3% to -5% | -5% to -8% | -12% to -20% | Sema/tirz modest vs statins; reta is stronger but not a statin substitute |
| CV Risk Reduction | 20% MACE ↓ (SELECT) | Trial ongoing | Trial pending | Semaglutide has the outcomes data |
GLP-1 Drugs and Statins
A common question: can GLP-1 agonists like Ozempic or Mounjaro replace statins?
No. Different mechanisms, different targets.
Statins block cholesterol synthesis in the liver, forcing it to pull LDL from the bloodstream. Result: 30-50% LDL reduction. Statins are the primary tool for LDL management.
GLP-1 drugs primarily reduce triglycerides, liver fat, and insulin-resistant metabolic pressure. Semaglutide and tirzepatide have modest LDL effects. Retatrutide's LDL effect is stronger, but still does not match moderate-to-high-intensity statin therapy.
The combination makes sense for many patients:
- Statin handles LDL (the primary driver of atherosclerotic plaque)
- GLP-1 drug handles triglycerides, weight, liver fat, and overall metabolic health
The SELECT trial enrolled patients where 70% were already on statins. Semaglutide's cardiovascular benefits were additive — on top of statin therapy, not instead of it.
Timeline: When to Expect Changes
Lipid improvements track with weight loss and metabolic adaptation:
- Weeks 4-8: Early triglyceride changes may appear
- Weeks 12-16: More substantial improvements as weight loss accumulates
- Week 24+: Lipid panel typically reflects the new metabolic state
For retatrutide specifically, the direct hepatic effects may produce faster liver fat reduction than weight loss alone would predict — but this hasn't been formally studied with serial imaging.
Key Takeaways
- All GLP-1 drugs improve lipids, with triglycerides responding most dramatically (15-45% depending on drug).
- Retatrutide > Tirzepatide > Semaglutide is the practical hierarchy for triglycerides and liver fat. HDL is not part of that hierarchy; retatrutide does not clearly improve HDL.
- The difference is glucagon. Semaglutide and tirzepatide improve lipids primarily through weight loss and insulin improvement. Retatrutide adds a liver-facing signal that shifts fat handling directly.
- For liver fat specifically, retatrutide's 86% MASLD-substudy reduction is qualitatively different from the semaglutide and tirzepatide imaging signals. If fatty liver or severe hypertriglyceridemia is the concern, this distinction matters.
- LDL reduction is modest for semaglutide and tirzepatide (3-8%). Retatrutide can reach about 20% at high dose through a different liver-lipid pathway, but statins remain primary LDL therapy.
FAQ
Do GLP-1 drugs reduce triglycerides?
Yes, substantially. Semaglutide reduces triglycerides by 15-25%, tirzepatide by 20-30%, and retatrutide by 35-45%. Triglycerides are the lipid parameter most responsive to GLP-1 therapy because these drugs reduce liver fat — and the liver is where triglyceride-rich particles are assembled.
How does retatrutide lower cholesterol differently than Ozempic or Mounjaro?
Retatrutide activates glucagon receptors in addition to GLP-1 and GIP. Glucagon gives the liver a direct fat-burning signal instead of only reducing how much fat arrives there. In the MASLD-selected substudy, that produced 86% liver-fat reduction; in the obesity trial, higher doses produced 35-45% triglyceride cuts.
For LDL specifically, retatrutide has an additional mechanism: glucagon receptor activation reduces hepatic ANGPTL3/8¹⁰ secretion, increasing lipoprotein lipase (LPL) activity and pulling more lipid out of the bloodstream. This produced ~20% LDL reduction at the highest dose in phase 2 — approaching low-dose statin territory through a completely different pathway than statins use.
Semaglutide and tirzepatide improve lipids primarily through weight loss; retatrutide adds both direct hepatic fat burning and a pharmacological LDL-lowering mechanism.
Does Ozempic lower cholesterol?
Yes. Semaglutide reduces triglycerides by 15-22% and LDL by 3-5% in clinical trials. The triglyceride effect is more pronounced than the LDL effect. These improvements are primarily driven by weight loss and reduced liver fat production.
Does Mounjaro lower cholesterol?
Yes, and somewhat more than Ozempic. Tirzepatide reduces triglycerides by 20-30% and LDL by 5-8%. The added GIP receptor activation and greater weight loss likely explain the stronger lipid effects compared to semaglutide.
Which GLP-1 drug is best for fatty liver?
Depends on the endpoint. For raw liver-fat reduction on MRI, retatrutide leads by a wide margin: the MASLD-selected substudy produced an 86% reduction with 93% of high-dose patients achieving complete resolution². Tirzepatide is the strongest approved option, with about a 50% placebo-adjusted liver-fat reduction in the non-diabetic SURMOUNT-J MRI data and a similar directional signal in T2D MRI data. For histologic MASH resolution, the biopsy-confirmed endpoint, semaglutide and tirzepatide are already strong: ESSENCE recorded 62.9% resolution on semaglutide 2.4 mg vs 34.1% placebo, and SYNERGY-NASH recorded 62% on tirzepatide 15 mg vs 10% placebo. Retatrutide's MASH biopsy data is not published yet.
Can GLP-1 drugs replace statins for cholesterol?
No. Semaglutide and tirzepatide reduce LDL by only 3-8%, while statins often reduce LDL by 30-50%. Retatrutide's ~20% LDL reduction is more meaningful, but it still does not match moderate-dose statins and works through a different lipid-handling pathway.
For LDL management, statins remain primary therapy. GLP-1 drugs are better understood as complementary — they handle triglycerides, liver fat, and metabolic health while statins handle LDL. The combination is additive: in the SELECT trial, 70% of participants were already on statins, and semaglutide's cardiovascular benefits stacked on top.
Can I reduce my statin dose on a GLP-1?
Probably not on the basis of the GLP-1 alone. Statins handle LDL (30-50% reduction) through a different mechanism than GLP-1 drugs, which move triglycerides and liver fat primarily. The SELECT trial's 20% MACE reduction occurred on top of statin therapy (70% of participants were already on statins at baseline), not in place of it — the benefits were additive, not substitutive¹. If your LDL improves on a GLP-1, that improvement is largely weight-loss-mediated; statin decisions belong with your clinician based on repeat lipid panels and overall ASCVD risk, not on the GLP-1 reading alone.
Do I need to take a GLP-1 drug forever, like a statin?
For semaglutide and tirzepatide, probably yes. The STEP-1 extension study showed that people who stopped Ozempic regained about two-thirds of lost weight within a year. Metabolic improvements — including lipid changes — reversed along with it. The drugs suppress appetite. Stop the drug, appetite returns, weight returns, lipids worsen. If you're planning to come off either, see Stopping GLP-1s for the taper and maintenance framework that holds losses better than cold turkey.
Retatrutide may differ on liver fat because it directly clears hepatic fat while the drug is active. But there is no human retatrutide withdrawal trial showing lipid durability after stopping. The safer read is simple: if weight, waist, insulin resistance, or liver fat returns, the lipid panel can drift back too. Maintenance still matters.
What's the difference between Ozempic and Wegovy? Mounjaro and Zepbound?
Same drugs, different doses and indications:
| Brand | Drug | Dose | Indication |
|---|---|---|---|
| Ozempic | Semaglutide | Up to 2mg | Type 2 diabetes |
| Wegovy | Semaglutide | 2.4mg | Obesity/weight loss |
| Mounjaro | Tirzepatide | Up to 15mg | Type 2 diabetes |
| Zepbound | Tirzepatide | Up to 15mg | Obesity/weight loss |
The lipid effects are the same because the active drug is the same. Wegovy and Zepbound use higher doses optimized for weight loss, which may produce somewhat greater lipid improvements than the diabetes doses — but the mechanism is identical.
Related Topics
- GLP-1 Comparison Guide — full breakdown of semaglutide vs tirzepatide vs retatrutide
- Semaglutide Guide — dosing, side effects, and results
- Semaglutide Dosing Calculator — reconstitution math for 5/10/20mg vials
- Tirzepatide Guide — the dual-agonist option
- Tirzepatide Dosing Calculator — reconstitution math for 10/20/30mg vials
- Retatrutide Guide — the triple-agonist with strongest lipid effects
- Retatrutide Dosing Calculator — reconstitution math for 10/12/24mg vials
References
¹ Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131.
² Harrison SA, et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30(7):2018-2028. PMID: 38858523.
³ Tirzepatide liver-fat anchors — SURMOUNT-J non-diabetic obesity MRI data for the ~50% placebo-adjusted liver-fat reduction; Gastaldelli A, et al. SURPASS-3 MRI for the T2D MRI direction.
⁴ Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
⁵ Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002.
⁶ Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
⁷ Newsome PN, et al. Semaglutide in Patients with Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE). N Engl J Med. 2025. PMID: 40305708.
⁸ Loomba R, et al. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH). N Engl J Med. 2024. PMID: 38856224.
⁹ Aronne LJ, et al. Tirzepatide versus Semaglutide for Obesity (SURMOUNT-5). N Engl J Med. 2025. — head-to-head, 20.2% vs 13.7% weight loss at 72 weeks.
¹⁰ Wen D, et al. Retatrutide lipid mechanism. Diabetes Obes Metab. 2025;27:5985-5995. GCGR-linked ANGPTL3/8 suppression; PCSK9 did not meaningfully decrease versus placebo.
Medical Disclaimer
The content in this GLP-1 protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.